中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 2
Feb.  2025
Turn off MathJax
Article Contents

Research advances in the disease burden of viral hepatitis in China

DOI: 10.12449/JCH250205
More Information
  • Corresponding author: WANG Yu, wangyu@chinacdc.cn (ORCID: 0000-0002-7891-4633)
  • Received Date: 2024-11-30
  • Accepted Date: 2025-01-13
  • Published Date: 2025-02-25
  • Over the past three decades, China has made significant progress in the prevention and control of viral hepatitis, and the incidence rates of new-onset pediatric hepatitis B virus infections and acute viral hepatitis in the population have reduced to a relatively low level; however, there is still a heavy disease burden of chronic viral hepatitis in China, which severely affects the health status of the population. This study systematically summarizes the achievements of viral hepatitis prevention and control in China, analyzes existing problems and challenges, and proposes comprehensive prevention and control strategies and measures to eliminate viral hepatitis as a public health threat based on the national conditions of China, in order to provide a reference for related departments in China on how to achieve the action targets for eliminating viral hepatitis as a public health threat by 2030.

     

  • loading
  • [1]
    World Health Organization. Global health sector strategy on viral hepatitis 2016- 2021[EB/OL].( 2016-06)[ 2024-06-22]. https//www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. https//www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/
    [2]
    National Health and Family Planning Commission, National Development and Reform Commission, Ministry of Education, et al. Notice on the issuance of Action plan for the prevention and treatment of viral hepatitis in China by National Administration of Traditional Chinese Medicine(2017—2020)[J]. Gazette of the State Council of the People’s Republic of China, 2018,( 7): 76- 82.

    国家计生卫生委, 国家发展改革委, 教育部, 等. 中医药局关于印发中国病毒性肝炎防治规划(2017-2020年)的通知[J]. 中华人民共和国国务院公报, 2018,( 7): 76- 82.
    [3]
    National Health Commission of the People’s Republic of China. Action plan for eliminating hepatitis C as a public health threat( 2021- 2030 年)[EB/OL].( 2021-08-31)[ 2024-06-22]. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml?R0NMKk6uozOC=1654310439640. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml?R0NMKk6uozOC=1654310439640

    国家卫生健康委员会. 消除丙型肝炎公共卫生危害行动工作方案( 2021- 2030 年)[EB/OL].( 2021-08-31)[ 2024-06-22]. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml?R0NMKk6uozOC=1654310439640. http://www.nhc.gov.cn/jkj/s3586/202109/c462ec94e6d14d8291c5309406603153.shtml?R0NMKk6uozOC=1654310439640
    [4]
    General Office of National Health and Family Planning Commission, General Office of Ministry of Finance. Notice on the implementation of nucleic acid testing in blood stations[EB/OL].( 2015-03-02)[ 2024-06-22]. http://www.nhc.gov.cn/yzygj/s3589/201503/a93bcfaca8b04f2bbaa7eef064a8d522.shtml. http://www.nhc.gov.cn/yzygj/s3589/201503/a93bcfaca8b04f2bbaa7eef064a8d522.shtml

    国家卫生计生委办公厅, 财政部办公厅. 关于做好血站核酸检测工作的通知[EB/OL].( 2015-03-02)[ 2024-06-22]. http://www.nhc.gov.cn/yzygj/s3589/201503/a93bcfaca8b04f2bbaa7eef064a8d522.shtml. http://www.nhc.gov.cn/yzygj/s3589/201503/a93bcfaca8b04f2bbaa7eef064a8d522.shtml
    [5]
    XU JJ, HAN MJ, JIANG YJ, et al. Prevention and control of HIV/AIDS in China: Lessons from the past three decades[J]. Chin Med J(Engl), 2021, 134( 23): 2799- 2809. DOI: 10.1097/CM9.0000000000001842.
    [6]
    FU HC, XU J, ZHOU C, et al. Progress of community-based methadone maintenance treatment in China from 2004 to 2021[J]. Chin J AIDS STD, 2023, 29( 1): 28- 32. DOI: 10.13419/j.cnki.aids.2023.01.06.

    付鸿臣, 徐杰, 周楚, 等. 2004—2021年全国社区美沙酮维持治疗工作进展分析[J]. 中国艾滋病性病, 2023, 29( 1): 28- 32. DOI: 10.13419/j.cnki.aids.2023.01.06.
    [7]
    TANG L, LIU QQ, WANG XQ, et al. Interrupted time series analyses of hepatitis A incidence in different endemic areas of China before and after introduction of hepatitis A vaccine into the national Expanded Program on Immunization[J]. Chin J Vaccines Immun, 2022, 28( 1): 19- 25. DOI: 10.19914/j.CJVI.2022005.

    唐林, 刘倩倩, 王晓琪, 等. 中国扩大国家免疫规划前后不同流行区甲型肝炎报告发病率变化的中断时间序列分析[J]. 中国疫苗和免疫, 2022, 28( 1): 19- 25. DOI: 10.19914/j.CJVI.2022005.
    [8]
    Disease Prevention and Control Bureau, National Health Commission of the People’s Republic of China. An overview of national notifiable infectious diseases in 2021[EB/OL].( 2022-04-22)[ 2024-11-19]. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml

    国家卫生健康委员会疾病预防控制局. 2021年全国法定传染病疫情概况[EB/OL].( 2022-04-22)[ 2024-11-19]. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml. http://www.nhc.gov.cn/jkj/s3578/202204/4fd88a291d914abf8f7a91f6333567e1.shtml
    [9]
    WANG FZ, ZHENG H, SUN XJ, et al. Achievements and prospects for hepatitis B prevention and control in China[J]. Chin J Vaccines Immun, 2019, 25( 5): 487- 492. DOI: 10.19914/j.cjvi.2019.05.001.

    王富珍, 郑徽, 孙校金, 等. 中国控制乙型病毒性肝炎的成就与展望[J]. 中国疫苗和免疫, 2019, 25( 5): 487- 492. DOI: 10.19914/j.cjvi.2019.05.001.
    [10]
    ZHENG H, WANG Y, WANG FZ, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: Evidence from the fourth national serological survey, 2020[J]. Lancet Reg Health West Pac, 2024, 51: 101193. DOI: 10.1016/j.lanwpc.2024.101193.
    [11]
    ZHAO XY, LI M, WANG H, et al. Impact of national centralized drug procurement policy on antiviral utilization and expenditure for hepatitis B in China[J]. J Clin Transl Hepatol, 2022, 10( 3): 420- 428. DOI: 10.14218/JCTH.2022.00167.
    [12]
    ZENG HM, CHEN WQ, ZHENG RS, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6( 5): e555- e567. DOI: 10.1016/S2214-109X(18)30127-X.
    [13]
    HE J, CHEN WQ. China cancer registry annual report[M]. Beijing: People’s Medical Publishing House, 2018.

    赫捷, 陈万青. 2017中国肿瘤登记年报[M]. 北京: 人民卫生出版社, 2018.
    [14]
    WANG SM, ZHENG RS, HAN BF, et al. Age distribution of cancer incidence and mortality in China in 2022[J]. China Cancer, 2024, 33( 3): 165- 174. DOI: 10.11735/j.issn.1004-0242.2024.03.A001.

    王少明, 郑荣寿, 韩冰峰, 等. 2022年中国人群恶性肿瘤发病与死亡年龄特征分析[J]. 中国肿瘤, 2024, 33( 3): 165- 174. DOI: 10.11735/j.issn.1004-0242.2024.03.A001.
    [15]
    WANG XX, LIU HX, QI JL, et al. Trends in mortality of cirrhosis in China: An analysis of the China death surveillance database from 2008 to 2020[J]. J Clin Transl Hepatol, 2024, 12( 3): 236- 244. DOI: 10.14218/JCTH.2023.00454.
    [16]
    ZHENG RS, CHEN R, HAN BF, et al. Cancer incidence and mortality in China, 2022[J]. Chin J Oncol, 2024, 46( 3): 221- 231. DOI: 10.3760/cma.j.cn112152-20240119-00035.

    郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46( 3): 221- 231. DOI: 10.3760/cma.j.cn112152-20240119-00035.
    [17]
    QI JL, LI ML, WANG LJ, et al. National and subnational trends in cancer burden in China, 2005-20: An analysis of national mortality surveillance data[J]. Lancet Public Health, 2023, 8( 12): e943- e955. DOI: 10.1016/S2468-2667(23)00211-6.
    [18]
    LIU Y, ZHENG JX, HAO JL, et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019[J]. Cancer Med, 2022, 11( 5): 1310- 1323. DOI: 10.1002/cam4.4551.
    [19]
    WANG X, LIN SX, TAO J, et al. Study of liver cirrhosis over ten consecutive years in Southern China[J]. World J Gastroenterol, 2014, 20( 37): 13546- 13555. DOI: 10.3748/wjg.v20.i37.13546.
    [20]
    WANG MJ, WANG YT, FENG XS, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center[J]. Int J Infect Dis, 2017, 65: 15- 21. DOI: 10.1016/j.ijid.2017.09.003.
    [21]
    QIN SK. Interim report of China Liver Cancer Survey(CLCS)[C]. The 22nd National Congress of Clinical Oncology and 2019 CSCO Academic Conference, Xiamen, 2019.

    秦叔逵. 中国原发性肝癌临床登记调查(CLCS)的中期报告[C]. 第22届全国临床肿瘤学大会暨2019年CSCO学术会议, 厦门, 2019.
    [22]
    National Health Commission of the People’s Republic of China. China Health Yearbook 2022[EB/OL].( 2023-05-17)[ 2024-06-22]. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb/files/b05b3d958fc546d98261d165cea4adba.pdf. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb/files/b05b3d958fc546d98261d165cea4adba.pdf

    国家卫生健康委员会. 2022中国卫生健康统计年鉴[EB/OL].( 2023-05-17)[ 2024-06-22]. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb/files/b05b3d958fc546d98261d165cea4adba.pdf. http://www.nhc.gov.cn/mohwsbwstjxxzx/tjtjnj/202305/6ef68aac6bd14c1eb9375e01a0faa1fb/files/b05b3d958fc546d98261d165cea4adba.pdf
    [23]
    HAN MJ, CHEN QF, XU P, et al. Striving for the new journey of AIDS prevention and control during the 13th Five-Year Plan: Retrospects and prospects of AIDS prevention and control in China[J]. Chin J AIDS STD, 2021, 27( 12): 1327- 1331. DOI: 10.13419/j.cnki.aids.2021.12.01.

    韩孟杰, 陈清峰, 徐鹏, 等. 砥砺奋进“十三五”艾滋病防控迈向新征程: 我国艾滋病防治回顾与展望[J]. 中国艾滋病性病, 2021, 27( 12): 1327- 1331. DOI: 10.13419/j.cnki.aids.2021.12.01.
    [24]
    XIAO HP. New advances in the prevention and treatment of tuberculosis[M]. Shanghai: Fudan University Press, 2004.

    肖和平. 结核病防治新进展[M]. 上海: 复旦大学出版社, 2004.
    [25]
    World Health Organization. Global tuberculosis report 2020[EB/OL].( 2022-10-14)[ 2024-11-21]. https://iris.who.int/bitstream/handle/10665/336069/9789240013131-eng.pdf?sequence=1. https://iris.who.int/bitstream/handle/10665/336069/9789240013131-eng.pdf?sequence=1
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)

    Article Metrics

    Article views (2030) PDF downloads(231) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return